0000899243-18-030947.txt : 20181213
0000899243-18-030947.hdr.sgml : 20181213
20181213183935
ACCESSION NUMBER: 0000899243-18-030947
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181212
FILED AS OF DATE: 20181213
DATE AS OF CHANGE: 20181213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Enyedy Mark J
CENTRAL INDEX KEY: 0001586965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 181234236
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-12-12
0
0001517022
Akebia Therapeutics, Inc.
AKBA
0001586965
Enyedy Mark J
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2018-12-12
4
A
0
3743
A
3743
D
Stock Option (Right to buy)
19.56
2018-12-12
4
A
0
18716
A
2027-09-11
Common Stock
18716
18716
D
Stock Option (Right to buy)
10.05
2018-12-12
4
A
0
11229
A
2028-06-30
Common Stock
11229
11229
D
Stock Option (Right to buy)
8.94
2018-12-12
4
A
0
25000
0.00
A
2028-12-12
Common Stock
25000
25000
D
Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier").
The option is fully vested and currently exercisable.
Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.
25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
/s/ Nicole R. Hadas, Attorney-in-fact for Mark J. Enyedy
2018-12-13